MSLN and cancer: Additionally, statistically significant differences were observed between soluble MSLN levels of PC patients and that of healthy volunteers (p<0.001), but no significant differences between the plasma MSLN concentration in the cancer patients and that of the benign pancreatic disease patients (p = 0.17) (Figure 1).